{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:51:58Z","timestamp":1784821918096,"version":"3.55.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.schres.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T17:38:06Z","timestamp":1705426686000},"page":"370-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Letter to the editor: Comments on \u201cPrevalence and predictors of QTc prolongation in patients seen in a clozapine clinic in a real-world setting in Australia\u201d"],"prefix":"10.1016","volume":"264","author":[{"given":"Timothy","family":"Tanzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Winckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Isoardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Andric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2024.01.003_bb0005","doi-asserted-by":"crossref","DOI":"10.1177\/20451253221104947","article-title":"Estimation of cardiac QTc intervals in people prescribed antipsychotics: a comparison of correction factors","volume":"12","author":"Andric","year":"2022","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2024.01.003_bb0010","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/JCP.0000000000001605","article-title":"Clozapine blood concentration predicts corrected QT-interval prolongation in patients with psychoses","volume":"42","author":"Kim","year":"2022","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2024.01.003_bb0015","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/acps.12700","article-title":"The impact of clozapine on hospital use: a systematic review and meta-analysis","volume":"135","author":"Land","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.schres.2024.01.003_bb0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00210-022-02314-3","article-title":"The atypic antipsychotic clozapine inhibits multiple cardiac ion channels","volume":"396","author":"Le Marois","year":"2023","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.schres.2024.01.003_bb0025","doi-asserted-by":"crossref","first-page":"0","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?","volume":"74","author":"Nielsen","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2024.01.003_bb0030","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?","volume":"74","author":"Nielsen","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2024.01.003_bb0035","article-title":"Prevalence and predictors of QTc prolongation in patients seen in a clozapine clinic in a real-world setting in Australia","author":"Sankaranarayanan","year":"2023","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2024.01.003_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eurpsy.2013.08.001","article-title":"Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia","volume":"29","author":"Schneider","year":"2014","journal-title":"Eur. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2024.01.003_bb0045","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.01.003_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF03256196","article-title":"Investigation of the potential of clozapine to cause torsade de pointes","volume":"21","author":"Warner","year":"2002","journal-title":"Adverse Drug React. Toxicol. Rev."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T01:45:07Z","timestamp":1724723107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":10,"alternative-id":["S0920996424000033"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.01.003","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter to the editor: Comments on \u201cPrevalence and predictors of QTc prolongation in patients seen in a clozapine clinic in a real-world setting in Australia\u201d","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}